PHIO - יחס חוב להיוון בספרים RXi Pharmaceuticals

High competition in the nucleic acid delivery niche is weighing on the finances of Phio Pharmaceuticals (PHIO). Debt obligations relative to the balance sheet capital structure on the GURU.Markets chart illustrate the current burden, where the value of 0.00 records the metric level. Optimization is possible through the success of INTASYL trials, securing investments, and the monetization of its unique self-delivering RNA platform for cancer treatment.

This indicator measures the proportion of debt obligations relative to the company's net asset value. An increasing ratio signals overheating and the risk of a capital shortfall to cover debts. By analyzing the debt-to-capitalization financial stability metric, an investor assesses the company's actual leverage. For Phio Pharmaceuticals (PHIO), moderate leverage is critical when implementing ESG standards into RNA developments, ensuring ethical research without an excessive debt burden.